Immunotherapy Combination Shows Promising Long-Term Survival in Advanced Colorectal Cancer

New findings from a Phase 1b clinical trial (C-800-01) indicate that the immunotherapy combination of botensilimab and balstilimab (BOT+BAL) led to 51% of patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer surviving at least 18 months. Notably, nearly a quarter of these long-term survivors remained alive without further anticancer treatment at their last follow-up. These results were released ahead of a presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.